Passa al contenuto
Merck
Tutte le immagini(4)

Key Documents

L9664

Sigma-Aldrich

Loratadine

≥98% (HPLC), powder

Sinonimo/i:

4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester, Loratidine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C22H23N2O2Cl
Numero CAS:
Peso molecolare:
382.88
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Livello qualitativo

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

white

Solubilità

DMSO: soluble 50 mg/mL
H2O: insoluble

Ideatore

Schering Plough

Temperatura di conservazione

2-8°C

Stringa SMILE

CCOC(=O)N1CC\C(CC1)=C2/c3ccc(Cl)cc3CCc4cccnc24

InChI

1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
JCCNYMKQOSZNPW-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Loratadine is a non-sedating histamine H1-receptor antagonist. Shown to inhibit the two-pore domain potassium channel K2P18.1 (also called TRESK or KCNK18).
Non-sedating histamine H1-receptor antagonist.

Caratteristiche e vantaggi

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

Rupatadine

Sigma-Aldrich

CDS022916

Rupatadine

vibrant-m

Y0000604

Loratadine impurity F

Desloratadine United States Pharmacopeia (USP) Reference Standard

USP

1173042

Desloratadine

Desloratadine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1680

Desloratadine

Domperidone powder, ≥98% (HPLC)

Sigma-Aldrich

D122

Domperidone

Cetirizine ≥98% (HPLC)

Sigma-Aldrich

C3618

Cetirizine

Amikacin sulfate European Pharmacopoeia (EP) Reference Standard

A0365900

Amikacin sulfate

F M Baroody et al.
Allergy, 55 Suppl 64, 17-27 (2001-04-09)
The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells. This notion
Karsten Weller et al.
Acta dermato-venereologica, 93(2), 168-174 (2012-10-12)
Non-sedating H1-antihistamines are the recommended first-line treatment for chronic spontaneous urticaria. While efficacy studies usually apply continuous daily treatment regimens, many patients take their medication on demand. In this randomized, double-blind trial we tested whether on-demand H1-antihistamine desloratadine in standard
P Deep et al.
Synapse (New York, N.Y.), 34(4), 313-318 (1999-10-26)
The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine
F Estelle R Simons et al.
The Journal of allergy and clinical immunology, 110(5), 777-783 (2002-11-06)
The extent of the distribution of H(1)- antihistamines into the skin and H(1)-antihistamine activity in the skin are clinically relevant in the treatment of allergic skin disorders. In a prospective, randomized, double-blind, parallel-group, multiple-dose study, we gave fexofenadine 180 mg
M Magerl et al.
The British journal of dermatology, 166(5), 1095-1099 (2012-01-17)
Cold urticaria is a rare but severe and potentially lethal condition. It is primarily treated symptomatically with H(1) -antihistamines. However, patients have a variable response to these drugs and, to date, it has not been possible to predict readily the

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.